Apimeds Pharmaceuticals US Inc (APUS)

AMEX · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Apimeds Pharmaceuticals US Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

Apimeds Pharmaceuticals US Inc is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based therapeutic administered through intradermal injection. The company operates through two subsidiaries and is conducting clinical trials for treating inflammation and pain associated with knee osteoarthritis and multiple sclerosis.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Apimeds Pharmaceuticals US Inc stock.

Our verdict on APUS

Not valued: We cannot value this company yet.

ETFs with the most weight in APUS

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than APUS in Drug Manufacturers - Specialty & Generic

33 more in this industry show a wider margin of safety.

Is APUS undervalued or overvalued?

We do not publish a verdict on APUS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of APUS?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.